Advertisement
UK markets close in 4 hours 41 minutes

  • FTSE 100

    8,105.47
    +26.61 (+0.33%)
     

  • FTSE 250

    19,816.84
    +214.86 (+1.10%)
     

  • AIM

    755.58
    +2.46 (+0.33%)
     

  • GBP/EUR

    1.1659
    +0.0002 (+0.02%)
     

  • GBP/USD

    1.2510
    -0.0001 (-0.01%)
     

  • Bitcoin GBP

    51,331.38
    +467.71 (+0.92%)
     

  • CMC Crypto 200

    1,388.39
    -8.15 (-0.58%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     

  • GOLD FUTURES

    2,359.00
    +16.50 (+0.70%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,048.52
    +131.24 (+0.73%)
     

  • CAC 40

    8,031.03
    +14.38 (+0.18%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·3-min read

For the quarter ended March 2023, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $3.66 billion, representing no change compared to the same period last year. EPS came in at $0.40, compared to $0.55 in the year-ago quarter.

The reported revenue represents a surprise of +1.60% over the Zacks Consensus Estimate of $3.6 billion. With the consensus EPS estimate being $0.57, the EPS surprise was -29.82%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenue- International Markets: $492 million versus $493.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Geographic Revenue- North America: $1.77 billion versus $1.74 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.7% change.

  • Geographic Revenue- North America - COPAXONE: $76 million versus $75.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.6% change.

  • Geographic Revenue- North America - BENDEKA / TREANDA: $63 million versus the four-analyst average estimate of $65.49 million. The reported number represents a year-over-year change of -23.2%.

  • Geographic Revenue- North America - AUSTEDO: $170 million compared to the $210.16 million average estimate based on four analysts. The reported number represents a change of +10.4% year over year.

  • Geographic Revenue- North America - Anda: $424 million versus $365.05 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +24% change.

  • Geographic Revenue- Europe - COPAXONE: $59 million versus the four-analyst average estimate of $55.54 million. The reported number represents a year-over-year change of -18.1%.

  • Geographic Revenue- Europe - Respiratory products: $68 million versus $68.10 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.2% change.

  • Geographic Revenue- International Markets - Generic products: $400 million versus the four-analyst average estimate of $395.20 million.

  • Geographic Revenue- International Markets - COPAXONE: $12 million versus the four-analyst average estimate of $7.79 million. The reported number represents a year-over-year change of +20%.

  • Revenue- API sales to third parties: $132 million versus the three-analyst average estimate of $173.65 million. The reported number represents a year-over-year change of -27.1%.

  • Revenue- COPAXONE - Total: $147 million versus the three-analyst average estimate of $139.34 million.

View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>

Shares of Teva Pharmaceutical Industries Ltd. have returned -3.9% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research